SCHEMBL1796283

SCHEMBL1796283

COC(=O)c1cc(Cl)ccc1NC(=O)CCCCC(=O)Nc1scc(-c2ccccc2)c1C(=O)OC(C)(C)C

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 3/20 0.47
POLB P06746 2/20 0.47
ALDH1A1 P00352 10/20 0.44
TP53 P04637 1/20 0.44
LMNA P02545 7/20 0.42
SMN1; SMN2 Q16637 4/20 0.42
UBE2I P63279 1/20 0.42
SAE1 Q9UBE0 1/20 0.42
UBA2 Q9UBT2 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
HPGD P15428 4/20 0.42
KDM4E B2RXH2 2/20 0.42
NPC1 O15118 1/20 0.42
TSHR P16473 1/20 0.42
HSD17B10 Q99714 1/20 0.42
MAPT P10636 2/20 0.42
NPSR1 Q6W5P4 1/20 0.41
CNR2 P34972 1/20 0.41
PKM P14618 1/20 0.41
TDP1 Q9NUW8 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1798657 0.94 RAB9A (0.48) RAB9APOLBALDH1A1TP53LMNA
SCHEMBL1796957 0.93 RAB9A (0.47) RAB9APOLBALDH1A1TP53LMNA
SCHEMBL1796954 0.92 POLB (0.46) RAB9APOLBALDH1A1TP53LMNA
SCHEMBL1801503 0.90 ANO1 (0.50) RAB9APOLBALDH1A1PKMMEN1
SCHEMBL1799695 0.90 RAB9A (0.51) RAB9APOLBALDH1A1LMNASMN1; SMN2
SCHEMBL1800530 0.86 POLB (0.52) RAB9APOLBALDH1A1TP53LMNA
SCHEMBL1796259 0.86 RAB9A (0.52) RAB9APOLBALDH1A1LMNASMN1; SMN2
SCHEMBL1796981 0.85 RAB9A (0.51) RAB9APOLBALDH1A1LMNASMN1; SMN2
SCHEMBL1800214 0.84 RAB9A (0.56) RAB9APOLBALDH1A1LMNASMN1; SMN2
SCHEMBL1799358 0.83 RAB9A (0.62) RAB9APOLBALDH1A1LMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7951806-B2 Plasminogen activator inhibitor-1 inhibitor RENASCIENCE CO., LTD. (JP) 2011-05-31 US disclosed
US-20090124620-A1 PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR RENASCIENCE CO., LTD. (JP) 2009-05-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090124620-A1 PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR SERPINE1, SERPINC1, SERPINB1 RAB9A 2391/4885POLB 2674/4885ALDH1A1 800/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.